Jarrow Formulas N-A-C Recall: FDA Class II Mislabelling Exposes Supply Chain Vulnerabilities
Jarrow Formulas Inc initiated a Class II voluntary recall of 533 units of N-A-C (N-Acetyl-L-Cysteine) 500 mg capsules due to mislabeling with N-A-C Sustain 600 mg tablets. This event, now terminated, underscores critical supply chain and regulatory risks for procurement and quality assurance teams, highlighting the need for robust labeling verification processes to maintain consumer trust and market access in the United States.
FDA Class II Recall: Jarrow Formulas' N-A-C Mislabelling Incident
On October 9, 2020, Jarrow Formulas Inc, based in Los Angeles, CA, United States, initiated a Class II voluntary recall, designated D-0302-2021, for 533 units of its N-A-C (N-Acetyl-L-Cysteine) 500 mg capsules. This recall, which received its classification from the FDA on October 29, 2020, stemmed from a critical mislabeling error: bottles intended for N-A-C N-Acetyl-L-Cysteine 500 mg, 100 capsules (Product # 107002, UPC: 790011070023) were incorrectly filled or labeled with N-A-C Sustain 600 mg 100 tablets. The affected product belonged to Lot 65323G20 with an expiration date of July 2022. The distribution pattern for these mislabeled units was nationwide across the United States. For procurement directors, this incident highlights the paramount importance of rigorous quality control checks at every stage of the packaging and labeling process. A Class II recall indicates that the product could cause temporary or medically reversible adverse health consequences, or that the probability of serious adverse health consequences is remote. This means that while direct severe harm might be low, the potential for consumer confusion, incorrect dosage, or adverse reactions due to differing formulations presents a significant liability and reputational risk for any company in the chemical and life sciences sector. Supply chain VPs must recognize that even voluntary recalls, though firm-initiated, carry substantial operational and financial burdens, including reverse logistics and potential stock write-offs.
Jarrow Formulas Profile: N-Acetyl-L-Cysteine Product Portfolio and Facility Operations
Jarrow Formulas Inc, headquartered at 1824 S Robertson Blvd, Los Angeles, CA 90035-4317, United States, is a recognized entity in the dietary supplement market. The recalled product, N-A-C (N-Acetyl-L-Cysteine), is a prominent molecule in the nutraceutical space, valued for its antioxidant properties. The specific mislabeling involved two distinct N-A-C formulations: a 500 mg capsule and a 600 mg sustained-release tablet. This distinction is crucial for regulatory affairs heads and business development executives, as it underscores the need for precise product differentiation and labeling accuracy, especially when dealing with varying dosages and delivery mechanisms of the same active pharmaceutical ingredient (API) or supplement. The incident at Jarrow Formulas' Los Angeles operation, while not detailing specific facility observations beyond the mislabeling, signals potential gaps in their Good Manufacturing Practices (GMP) related to packaging lines and quality assurance protocols. For companies sourcing or distributing similar products, this event serves as a critical reminder that supplier due diligence must extend beyond API purity to encompass the entire manufacturing and packaging lifecycle. Any lapse can lead to market withdrawals, eroding consumer trust and market share, particularly for sensitive products like N-Acetyl-L-Cysteine which consumers rely on for specific health benefits.
Supply Chain and Procurement Impact: Navigating Mislabelling Recalls
The nationwide distribution of 533 mislabeled units of N-A-C by Jarrow Formulas Inc presents immediate and tangible challenges for procurement directors and supply chain VPs. While 533 units may seem modest, the logistical complexities and costs associated with a Class II recall are significant. This includes identifying affected batches, notifying distributors and retailers, coordinating product returns, and managing disposal or relabeling. Each step incurs costs, from transportation and warehousing to administrative overhead and potential penalties. For businesses that rely on Jarrow Formulas as a supplier, this event necessitates an immediate review of inventory, quarantine procedures, and customer communication strategies. Furthermore, the incident highlights the critical importance of robust supplier qualification processes. Procurement teams must move beyond basic financial and quality audits to scrutinize a supplier's packaging and labeling controls, deviation management, and recall readiness. A mislabeling event, even if quickly resolved, can disrupt downstream manufacturing schedules, impact product availability, and damage brand reputation, particularly in competitive markets like the United States where consumer expectations for product safety are high. Regulatory affairs heads should also note that such incidents can trigger increased scrutiny from the FDA on a supplier's entire product portfolio.
Broader Regulatory Landscape: Implications for Quality Assurance and Compliance
The Jarrow Formulas N-A-C recall is not an isolated incident but reflects ongoing stringent regulatory oversight by the FDA across the chemical and life sciences industries. This event, classified as Class II, underscores the FDA's persistent focus on product integrity and consumer safety, extending to dietary supplements. Recent parallel events in the industry further illustrate this heightened scrutiny. For instance, Essential Wellness Pharma faced a Class II recall for its Progesterone Injection due to sterility assurance failures, and Amgen's Tavneos market future was put at risk following an FDA hearing concerning independent data review. These examples, alongside the Jarrow Formulas recall, signal a clear trend: regulatory bodies are intensifying their enforcement actions, demanding impeccable quality management systems from manufacturers. For regulatory affairs heads, this means that compliance strategies must be proactive, not reactive, encompassing robust quality assurance programs, comprehensive risk assessments, and continuous monitoring of regulatory intelligence. Business development executives considering partnerships or acquisitions must factor in a potential target's regulatory history and compliance track record, as past incidents can significantly impact future market access and operational costs. The cost of non-compliance, both financial and reputational, far outweighs the investment in preventative quality measures.
Recall Resolution and Future Compliance Outlook for Jarrow Formulas
The voluntary recall initiated by Jarrow Formulas Inc for its mislabeled N-A-C products was officially terminated by the FDA on April 9, 2021. The termination of a recall signifies that the firm has successfully completed all necessary actions to remove or correct the violative product from the market. For Jarrow Formulas, this resolution indicates that they likely implemented corrective and preventive actions (CAPA) to address the root cause of the mislabeling, such as enhancing their packaging line controls, improving batch record review, or upgrading their quality management system. While the immediate crisis is resolved, the long-term implications for Jarrow Formulas and its stakeholders are notable. Regulatory affairs heads should understand that while the recall is terminated, the event remains part of the company's compliance record, potentially influencing future FDA inspections or product approvals. Procurement directors should conduct a post-recall audit with Jarrow Formulas to understand the CAPA implemented and assess the robustness of their updated quality systems to prevent recurrence. This proactive engagement is crucial for maintaining supply chain integrity and mitigating future risks. Business development executives must consider how such events, even when resolved, can impact brand perception and market positioning, necessitating transparent communication and a renewed commitment to quality to rebuild consumer confidence in the United States market.
Strategic Imperatives for Chemical and Life Sciences Executives
The Jarrow Formulas N-A-C mislabeling recall provides several critical strategic imperatives for senior decision-makers across the global chemical and life sciences industry. Firstly, procurement directors must prioritize supplier qualification processes that include in-depth audits of packaging and labeling controls, not just raw material quality. This involves verifying the segregation of different product strengths and formulations on production lines, as well as the robustness of final product inspection. Secondly, supply chain VPs need to develop agile recall management protocols, ensuring rapid identification, containment, and retrieval of affected products to minimize market exposure and financial impact. The ability to execute a swift and effective recall, as Jarrow Formulas demonstrated with its voluntary action, is a key differentiator in maintaining regulatory compliance and consumer trust. Thirdly, regulatory affairs heads must foster a culture of proactive compliance, leveraging internal audits and continuous training to prevent deviations before they escalate into recall events. This includes staying abreast of FDA guidance on labeling requirements for dietary supplements and pharmaceuticals. Finally, business development executives should recognize that product quality and regulatory compliance are integral to brand equity and market access. Investing in robust quality systems and transparent communication strategies post-incident is essential for long-term growth and maintaining a competitive edge in the United States and global markets.